The problem
Insulin-producing cells release a hormone that helps control blood sugar. A protective implant could hold those cells away from immune cells while letting glucose reach them and insulin leave. Can one device keep this blood-sugar response strong enough while supplying oxygen, protecting and containing the cells, and allowing them to be removed completely?[1] [2]
An implant full of insulin-producing cell clusters must let glucose in and insulin out quickly enough to respond to blood sugar. Can one removable device do that at a useful human cell dose while keeping the cells protected and oxygenated? A March 2026 design supplies oxygen by splitting water vapor, using inductive power transmitted from outside the body. Its membranes contain the islets and its gas-distribution layer delivers oxygen. Particular rodent grafts reversed diabetes for 90 days; human stem-cell-derived islets in mice gave partial glucose control. The healthy-primate experiment showed about one month of islet survival, not treatment of primate diabetes.[1] [2]
Scope
An implanted, surgically manageable and completely retrievable cell-containing bioartificial pancreas providing reproducible, therapeutically meaningful glucose-responsive endocrine function at a meaningful cell dose while jointly maintaining oxygen/nutrient transport, immune protection, containment and mechanical integrity. This is device qualification, not the biological origin of diabetes or an injected-cell therapy without this containment architecture.
What remains open
Devices have already reversed diabetes in rodents, and an oxygen-generating implant has supported islets in a healthy monkey. What remains is reliable, useful endocrine output from a manageable human-scale device that also contains its cells, tolerates its surroundings and can be completely removed.[1] [2]
Scaling that result requires a therapeutic cell dose without creating an oxygen-starved interior, a delayed glucose/insulin response or an impractical footprint. Active oxygenation changes the failure boundary: the implant may lack an internal battery, but the demonstrated system still uses an external power platform. The primate protocol included power-system maintenance, so its success cannot establish maintenance-free clinical operation.[1] [2]
Why it matters
Living cells respond to glucose through their own biology, offering a different route from an electronic glucose sensor driving an insulin pump. Containment and retrieval give clinicians control over the implanted cell population. These benefits depend on the device working as a complete system, including its oxygen supply and barriers.[1]
Living insulin-producing cells offer a route to blood-sugar control in which the therapeutic material itself responds to glucose and releases insulin. The implant must preserve that biological response while separating the donor cells from immune injury. This links a feedback function to a physical containment system: cells that remain alive but release too little insulin do not deliver the intended control. Complete retrieval gives a way to remove that cell population if the system fails. Rodent glucose control and healthy-primate survival test different parts of this proposal; neither establishes the combined human function. External oxygen-support equipment also remains part of what must keep working.[1] [2]
Research directions
2 directions to explore
Measure dose-dependent dynamic transport
Evaluate oxygenation and glucose-responsive secretion at the same cell loading and geometry intended for implantation, including the additional transport resistance of host response.
Qualify containment and retrieval together
Assess soluble immune injury, hydrated integrity, oxygen-support failure and complete removal of therapeutic cells in the actual device configuration.
Definitions
2 terms
islets
Clusters of cells containing the cells that produce insulin. An implant must supply them with oxygen and let glucose and insulin move through its protective barrier.[1] [2]
inductive power
Power transferred using linked magnetic fields between coils. The demonstrated implant receives energy from equipment outside the body, which still needs its own power supply.[2]
Sources
Partial results
Wireless oxygenating macrodevices supported 90-day rodent diabetes reversal and one-month nonhuman-primate islet survival. Scope: Subcutaneous rodent grafts and an initial experiment in a healthy nonhuman primate, without pharmacological immunosuppression.
Primate survival is not diabetes reversal or human therapeutic function. Battery-free implants still require external power, and primate Methods record battery changes and antenna replacements.
Source date: 2026-03-26Primary indexed Summary and Results separate rodent reversal, partial control from human stem-cell-derived islets in mice, and primate survival; Methods describe the external power platform.Read the source ↗- Engineering an Implantable Bioartificial Pancreas to Balance Transport, Containment, and Retrieval
Notes on Engineering an Implantable Bioartificial Pancreas to Balance Transport, Containment, and Retrieval
Actual PubMed abstract obtained through Europe PMC CORE metadata. Explicit unresolved clinical target and coupled transport, soluble immune injury, oxygen-support failure and complete retrieval constraints. Full review is subscription-only and was not read.
- Wireless battery-free oxygenation devices enable extended immunosuppression-free islet transplantation in minimally invasive sites
Notes on Wireless battery-free oxygenation devices enable extended immunosuppression-free islet transplantation in minimally invasive sites
Actual indexed publisher Summary, Results, figure descriptions and primate Methods: rodent glucose control, active water-vapor electrolysis and external inductive power platform; healthy-primate survival is separate from diabetes reversal. Direct publisher access returned 403; no complete supplementary access is claimed.